In the run up to Oxford Global's 6th Annual NGS Asia Congress they are delighted to invite you to see their free webinar recording.
'Current And Future Next Generation Sequencing Technologies'. Presented by David Smith, Professor and Consultant, Mayo Clinic
- History of NGS
- Why Illumina currently controls the NGS space
- Emergence of single molecule sequencers?
- Other NGS technologies
- NGS and clinical practice
- Where are we going?
Benefits to viewing the webinar include:
- ￼ Get an understanding of why NGS is still so important today
- Receive an overview of Illumina and its role in the NGS market
- Gain information on other technologies
- Hear about how these technologies help NGS in clinical applications and what is in store for the future of NGS
Who should see the webinar recording?
This webinar is for NGS professionals and those interested in hearing about NGS technologies and applications in clinical practice. It is for those who are based in Europe and the US who would like to hear views from a leading expert on NGS Platforms and Therapeutic Applications.
The Webinar Presenter:
Dr. David I Smith received his Ph.D. In Biochemistry from the Department of Biochemistry at the University of Wisconsin. His laboratory has been working on studying the common fragile sites, regions of profound instability found in all individuals. His group also studies the different roles that human papillomavirus plays in the development of different cancers. He is also the Chairman of the Technology Assessment Group for the Center for Individualized Medicine at the Mayo Clinic. His group uses next generation sequencing technologies to answer research questions. In addition, they are focused on translating basic science discoveries into new ways to treat patients with cancer.
Click here to see the webinar recording for free
If you would like further information regarding the 6th Annual Next Generation Sequencing Asia Congress then please contact Danielle Dalby on firstname.lastname@example.org. Alternatively visit the website.